Recently, the innovative product Youluohua in the field of Roche's blood diseases? The official commercial launch of Vipotuzumab in China marks a new treatment option for diffuse large B-cell lymphoma in China. Lymphoma is one of the most common blood tumors. The relevant data shows that the overall five-year survival rate of lymphoma in China is only 38.4%, which still falls short of the goal of reaching 46.6% for overall cancer patients by 2030 proposed in the "Healthy China 2030 Plan Outline". In recent years, innovative therapies and cutting-edge treatment technologies for lymphoma have emerged, providing an opportunity to further improve the diagnosis and treatment level of lymphoma and improve patient prognosis, bringing more expectations to patients with hematological diseases, and also making patients have a more urgent need for the accessibility of innovative drugs. There are many types of lymphoma, and the treatment needs of patients are becoming increasingly diverse, "said Gu Hongfei, founder of Lymphoma Home, In recent years, the economic burden of patients and their families facing treatment has always been the most concerned issue among the patient community. We hope that the national multi-level medical security system can be further improved, and on the basis of basic medical insurance, more and more innovative payment methods can be expanded to allow more and more patients to benefit from innovative therapies. Since 2020, with the support of innovative policies in the domestic drug regulatory field, Youluo Hua? As one of the urgently needed innovative drugs for the clinical treatment of lymphoma, it has been included in the drug catalog for clinical use through pilot policies in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, the Guangdong Hong Kong Macao Greater Bay Area, and the Tianjin Free Trade Zone. Meanwhile, according to government information, regional commercial supplementary medical insurance, including Tianjin Huimin Insurance and Hainan Boao Lecheng Global Special Drug Insurance, has included them in the scope of innovative special drug protection. (New News Agency)